期刊文献+

RRM1在晚期非小细胞肺癌中的表达及其意义

Expression and significance of RRM1 protein in advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中核苷酸还原酶M1(RRM1)的表达水平及其与NSCLC患者病情进展及预后的关系。方法:免疫组织化学法检测60例晚期NSCLC患者肺组织中RRM1蛋白表达水平,并与患者的临床特征及预后关系进行分析。结果:RRM1的表达与性别有统计学差异(P<0.05);与年龄、组织学类型及分期均无统计学差异(P>0.05)。在对生存期的分析中发现RRM1低表达组的中位生存期(18个月)及无疾病进展期(6个月)均明显长于高表达组(13个月,4个月)(P<0.05),1年生存率(69.2%)及2年生存率(23.1%)均高于高表达组(58.8%,3%)(P<0.05)。结论:晚期非小细胞肺癌组织中RRM1低表达的患者比高表达患者有更长的中位生存期及无疾病进展生存期。因此,RRM1表达水平可作为晚期NSCLC的一个重要的预测预后的标志物。 Objective: To investigate the expression level of ribonucleotide reductase M1 (RRM1) and the rela- tionship with NSCLC patients progress and prognosis in advanced non -small cell lung cancer(NSCLC). Methods: Tumor samples obtained from 60 patients with advanced NSCLC were collected to investigate the expression level of RRM1 by immunohistochemical methods. Relationships between the expression and clinical characters, prognostic of patients with advanced NSCLC were analyzed. Results:There was difference between RRM 1 expression and gender (P 〈 0.05 ), while there was no correlation between RRM 1 expression and age, histologic type and TNM stage (P 〉 0.05 ). Low expression group of RRM1 had longer overall survival (18 months, 13 months), longer no disease pro- gression period(6 months,4 months). There were higher 1 - year survival rate(69.2% ,58.8% ) and 2 - year surviv- al rate (23.1% ,3 % ) than over expression group of RRM1 ( P 〈 0.05 ). Conclusion: The patients of advanced non - small cell lung cancer with low RRM1 expression level had longer survival time. RRM1 expression level was an impor- tant prognostic factor for the patients in advanced non - small cell lung cancer.
作者 杨承纲 江波
出处 《现代肿瘤医学》 CAS 2013年第3期518-520,共3页 Journal of Modern Oncology
基金 云南省教育厅科学基金项目(编号:2010Y183)
关键词 晚期非小细胞肺癌 核苷酸还原酶M1 免疫组织化学 non- small cell lung cancer ribonucleotide reductase M1 immunohistochemstry
  • 相关文献

参考文献11

二级参考文献56

  • 1乔贵宾,吴一龙,区伟,杨学宁,钟文昭,林嘉颖,赵建,谢丹,关新元.免疫组化方法检测肿瘤标志在肺癌组织芯片中表达的可靠性研究[J].肿瘤防治研究,2004,31(8):467-470. 被引量:11
  • 2袁芃,缪小平,张雪梅,王中华,谭文,张湘茹,孙燕,徐兵河,林东昕.核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系[J].癌症,2005,24(12):1510-1513. 被引量:46
  • 3廖日强,林嘉颖,乔贵宾,骆新兰,杨衿记,黄玉娟,吴一龙.非小细胞肺癌组织芯片中RRM1表达和预后因子分析[J].中国肺癌杂志,2006,9(5):423-427. 被引量:20
  • 4Smid K,Bergman AM,Eijk PP,et al.Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits[J].Nucleosides Nucleotides Nucleic Acids,2006,25(9-11):1001-1007.
  • 5Bepler G,Kusmartseva I,Sharma S,et al.RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer[J].J Clin Oncol,2006,24(29):4731-4737.
  • 6Rosell R,Felip E,Taron M,et al.Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery[J].Clin Cancer Res,2004,10(12 Pt 2):4215s-4219s.
  • 7Rosell R,Cobo M,Isla D,et al.Applications of genomics in NSCLC[J].Lung Cancer,2005,50(Suppl 2):S33-40.
  • 8Seve P,Dumontel C.Chemoresistance in non-small cell lung cancer[J].Curr Med Chem Anticancer Agents,2005,5(l):73-88.
  • 9Smith BD,Karp JE.Ribonucleotide reductase:an old target with new potential[J].Leukemia Research,2003,27(12):1075-1076.
  • 10Rosell R,Danenberg KD,Alberola V,et al.Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2004,10(4):1318-1325.

共引文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部